{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 90 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '11.', 'DESCRIPTION OF GLOBAL AMENDMENT(S)', '11.1', 'GLOBAL AMENDMENT 1', 'Date of amendment', '30 Apr 2019', 'EudraCT number', 'Not applicable', 'EU number', 'BI Trial number', '1199-0324', 'BI Investigational Product(s)', 'nintedanib', 'Title of protocol', 'Study of Pulmonary Rehabilitation In', 'Nintedanib Treated Patients with IPF:', 'Improvements in Activity, Exercise Endurance', 'Time, and QoL', 'To be implemented only after approval of the IRB / IEC / Competent Authorities', 'X', 'To be implemented immediately in order to eliminate hazard -', 'IRB / IEC / Competent Authority to be notified of change with request for', 'approval', 'Can be implemented without IRB / IEC / Competent Authority approval as', 'changes involve logistical or administrative aspects only', 'Section to be changed', 'Title Page', 'Description of change', 'Updated the following:', 'Trial Clinical Monitor to Clinical Trial', 'Leader', 'Clinical Trial Leader to', 'Coordinating investigator to', 'Status', 'Version and Date of Protocol', 'Rationale for change', 'Administrative changes', 'Section to be changed', 'Clinical Trial Protocol Synopsis', 'Description of change', 'Updated the following:', 'Revision Date', 'Coordinating investigator to', 'Changed inclusion criteria from 18', 'months to 30 months', 'Rationale for change', 'Administrative changes. Updated from 18', 'months to 30 months to improve recruiting', 'opportunities.', 'Section to be changed', 'Flowchart', 'Description of change', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 91 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'Rationale for change', 'To provide more clarification as to when', 'incremental cycle ergometry will be conducted', 'and that the incremental and practice test can', 'both be done at Visit 1.', 'Section to be changed', 'Abbreviations Section', 'Description of change', 'Corrected spelling of words \"electronic,', 'association and idiopathic\".', 'Moved \"COPD\" to follow alphabetically.', 'Updated \"CML Clinical Monitor Local', 'and TCM Trial Clinical Monitor to CTM', 'Clinical Trial Manager and CTL Clinical', 'Trial Leader.', 'Rationale for change', 'Typo; administrative change.', 'Section to be changed', '3.1', 'Description of change', 'Changed 18 months to 30 months', 'Rationale for change', 'Administrative change. Updated from 18', 'months to 30 months to improve recruiting', 'opportunities.', 'Section to be changed', '3.2', 'Description of change', 'Corrected spelling of word \"positive\".', 'Changed 18 months to 30 months', 'Rationale for change', 'Typo; administrative change. Updated from 18', 'months to 30 months to improve recruiting', 'opportunities.', 'Section to be changed', '2.1.1', 'Description of change', 'Changed 18 months to 30 months', 'Rationale for change', 'Administrative change. Updated from 18', 'months to 30 months to improve recruiting', 'opportunities.', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 92 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'Section to be changed', '3.3.1', 'Description of change', 'Corrected spelling of word \"nintedanib\"', 'Changed 18 months to 30 months', 'Rationale for change', 'Typo; administrative change. Updated from 18', 'months to 30 months to improve recruiting', 'opportunities.', 'Section to be changed', '3.3.2', 'Description of change', 'Corrected spelling of word \"nintedanib\".', 'IC 1- changed 18 months to 30 months.', 'IC 8 - added per the instructions.', 'Potential sub-study patients that require', 'supplemental oxygen or cannot complete', 'the incremental or practice work rate', 'cycle ergometry test will not participate', 'in the sub-study, but will qualify for the', 'main study.\" to end of sentence.', 'Rationale for change', 'Typo; administrative change. Updated from 18', 'months to 30 months to improve recruiting', 'opportunities.', 'Section to be changed', '3.3.3', 'Description of change', 'EC 4 - added \"(except for rescreening as', 'described in Section 3.3).\" to end of sentence.', 'Rationale for change', 'To add more clarification regarding rescreens.', 'Section to be changed', '4.1.2', 'Description of change', 'Changed 18 months to 30 months.', 'Rationale for change', 'Updated from 18 months to 30 months to', 'improve recruiting opportunities.', 'Section to be changed', '4.1.4', 'Description of change', 'Changed 18 months to 30 months.', 'Rationale for change', 'Updated from 18 months to 30 months to', 'improve recruiting opportunities.', 'Section to be changed', '4.2.2.1', 'Description of change', 'Changed \"M\" to \"m\" in first and third', 'bullet.', 'Removed \".\" in first and third bullet.', 'Rationale for change', 'Administrative change.', 'Section to be changed', '4.2.2.2', 'Description of change', 'Removed \")\" after NAC and \"(\" after', 'pirfenidone.', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}